aap Implantate AG

  • WKN: 506660
  • ISIN: DE0005066609
  • Land: Deutschland

Nachricht vom 14.08.2020 | 15:48

Q2 and H1/2020: Tangible positive impact of restructuring on aap performance in challenging COVID-19 times

DGAP-News: aap Implantate AG / Key word(s): Half Year Results
14.08.2020 / 15:48
The issuer is solely responsible for the content of this announcement.

The COVID-19 pandemic led to a significant impairment of business operations at aap Implantate AG ("aap" or "Company") in recent months, which is reflected in the development of sales and earnings in the second quarter and first half of 2020. aap achieved sales of EUR 1.9 million in the second quarter of 2020 (Q2/2019: EUR 2.5 million) and EUR 4.4 million in the first six months (H1/2019: EUR 6.0 million). EBITDA was significantly impacted by one-time effects from the ongoing restructuring and refinancing as well as the revision of the quality management system and amounted to EUR -2.1 million in the second quarter of 2020 (Q2/2019: EUR -2.1 million) and in the first half-year to EUR -4.3 million (H1/2019:EUR -3.1 million). Excluding one-time effects, recurring EBITDA improved to EUR -1.5 million in the second quarter of 2020 (Q2/2019: EUR -1.6 million) and was only slightly below the previous year's level in the first six months at EUR -2.9 million (H1/2019: EUR -2.8 million). Overall, it can thus be stated that aap was almost able to absorb the negative effects of the COVID-19 pandemic through massive cost reduction and margin improvement, which at the same time reflects the progress made under the ongoing restructuring.
 

Q2/2020 and H1/2020 - Major results and progress

- Sales by region: Besides Germany (Q2: -22 %, H1: -26 %), international business (Q2: -42 %, H1: -45 %) particularly affected by the effects of the COVID-19 pandemic; resumption of business relations with original distribution partner in China and sales in Q2

- USA: Continued dynamic sales growth (Q2: +16%, H1: +32%); number of weekly operations sustainably stabilized at a level of up to 40 procedures; contracts with 5 US-wide purchasing associations and health networks as basis for planned growth of +30% in FY/2020

- Earnings: EBITDA in Q2 and H1 burdened by substantial one-time effects from restructuring, refinancing and revision of the QM system (Q2: EUR 0.7 million, H1: EUR 1.4 million); recurring EBITDA adjusted for one-time effects improved in Q2 (+10%) and only slightly below previous year's level in H1 (-2%) - progress of restructuring clearly visible despite massive Corona-related sales decline

- Gross margin and costs: Gross margin[1] improved to 88% in Q2 (Q2/2019: 83%) and 87% in H1 (H1/2019: 84%) thanks to discontinuation of standard trauma portfolio, reduction of headcount (to date approx. 30% vs. 31.12.2019) and improvement of product-customer mix; remarkable cost reduction through significant decrease in personnel expenses (-24% in Q2 and -12% in H1/2020)[2] and decreasing other costs (-45% in Q2 and -37% in H1/2020)[3]

- Cash flow and balance sheet: Cash holdings of EUR 0.8 million and equity ratio of 62%

- LOQTEQ(R): Focus on converting processes and documentation to meet increased regulatory requirements; new polyaxial LOQTEQ(R) VA foot system already successfully used several times in U.S.

- Silver coating technology: Approval by ethics commissions for conducting a human clinical study - all regulatory requirements for start of study in Germany fulfilled; test coatings performed for potential first joint development projects to be completed; ongoing discussions with global medical technology companies about potential co-financing of the study and further cooperation options

- Resorbable magnesium implant technology: FDA confirmation of probable classification as a particularly innovative "Novel" technology and qualification for faster "De Novo" approval process; further very promising results in pilot animal study with Colorado State University; ongoing discussions with technology-oriented investors to finance joint further development of technology

- Securing Company's financing: First shareholder loans from core shareholders in the amount of
EUR 0.4 million; ordinary capital reduction in the ratio of 10:1 approved by AGM; issue of convertible bond with total volume of up to around EUR 2.6 million; partial sale of excess capacities of the machinery initiated with additional proceeds of up to EUR 0.3 million


Q2/2020 and H1/2020 - Financials

Sales Q2/2020

In KEUR Q2/2020 Q2/2019[4] Change on year
Sales
Germany
USA[5]
USA distributors
USA global partners

International (without USA)
Europe (without Germany)
BRICS states
RoW5
1,874
549
584
559
25
741
257
230
254
2,473
702
502
496
6
1,269
433
192
644
-24%
-22%
+16%
+13%
>100%
-42%
-41%
+20%
-61%
Sales 1,874 2,473 -24%
 

Sales H1/2020

In KEUR H1/2020 H1/20194 Change on year
Sales
Germany
USA5
USA distributors
USA global partners

International (without USA)
Europe (without USA)
BRICS states
RoW5
4,353
1,115
1,343
1,131
212
1,895
792
488
615
5,974
1,508
1,014
993
22
3,451
1,065
1,013
1,373
-27%
-26%
+32%
+14%
>100%
-45%
-26%
-52%
-55%
Sales 4,353 5,974 -27%
 


With regard to the development of sales in the individual regions, it is apparent that, in addition to Germany (Q2: -22%, H1: -26%), international business (Q2: -42%, H1: -45%) was particularly affected by the effects of the COVID-19 pandemic, with a correspondingly significant decline in sales compared to the previous year. In particular foreign business, which is very important for aap (excluding the U.S.; around 60% of total sales in financial year 2019), has recently come to a virtual standstill. This hits the Company all the harder because the international partners with the highest sales are companies from Spain, South Africa, Brazil and Mexico. These countries are the most affected by the effects of the COVID-19 pandemic worldwide. By contrast, aap was able to generate sales again in China in the second quarter, where business relations with the original distribution partner were resumed.
 

In the United States, by contrast, aap remains on a good growth course and was able to increase sales substantially year-on-year both in the second quarter (+16%) and the first half (+32%). This is all the more remarkable since the U.S. is the country with the highest number of COVID-19 infections worldwide. Here, the momentum that began in the second half of 2019 continued and the number of procedures performed each week was sustainably stabilized at a level of up to 40 procedures. In addition, the newly concluded contracts with US-wide purchasing associations and health networks are beginning to bear fruit. At present aap already has contracts with five purchasing associations and health networks, which creates the basis for further growth. Overall, aap is aiming for a sales increase of at least 30% year-on-year in the U.S. in financial year 2020 despite COVID-19.
 

Q2 EBITDA

In KEUR Q2/2020 Q2/2019 Change
EBITDA -2,140 -2,146 0%
One-time effects 684* 534** +28%
Recurring EBITDA -1,456 -1,612 +10%

* Includes primarily restructuring and refinancing expenses (including personnel measures) and Project Quality First.
**Includes primarily restructuring and refinancing expenses (incl. personnel measures) and capitalization of development costs silver/magnesium.

 

H1 EBITDA

In KEUR H1/2020 H1/2019 Change
EBITDA -4,325 -3,144 -38%
One-time effects 1,421* 301** >+100%
Recurring EBITDA -2,904 -2,844 -2%

* Includes primarily restructuring and refinancing expenses (including personnel measures) and project Quality First.
** Includes capitalization of development costs silver/magnesium, restructuring and refinancing expenses (incl. personnel measures) and project Quality First.



Earnings, like sales, were strongly impacted by the COVID-19 pandemic in both the second quarter and the first half of 2020 and were significantly impacted by one-time effects from the ongoing restructuring and refinancing as well as the revision of the quality management system. At the same time, the ongoing restructuring measures are showing initial results, which can be summarized as follows:

- Improved gross margin (88% in Q2/2020 vs. 83% in Q2/2019 and 87% in H1/2020 vs. 84% in H1/2019), in particular as result of discontinuation of distribution of standard trauma portfolio at year end 2019 with simultaneous reduction in headcount and improved product-customer mix

- Headcount reduced by approx. 30% to date compared to 31.12.2019 (31.12.2019: 149 employees); decline in personnel expenses (excluding restructuring expenses) in Q2/2020 and H1/2020 by EUR 0.5 million year-on-year

- Declining trend in other costs (excluding restructuring and refinancing costs as well as one-time expenses in connection with the revision of the QM system) by EUR 1.0 million in Q2/2020 and by EUR 1.4 million in H1/2020


Based on the developments described above, EBITDA in the second quarter of 2020 was EUR -2.1 million (Q2/2019: EUR -2.1 million) and in the first half of the year EUR -4.3 million (H1/2019: EUR -3.1 million). Excluding one-time effects, recurring EBITDA improved to EUR -1.5 million in the second quarter of 2020 (Q2/2019: EUR -1.6 million). On a half-yearly basis, recurring EBITDA decreased slightly to EUR -2.9 million (H2/2019: EUR -2.8 million). All in all, this reflects the targeted development: focus on established markets with higher profit margins and sustainable streamlining of the cost structure to improve operating performance.
 

With a view to the further restructuring of the Company, aap has also initiated a partial sale of excess capacities of its machinery that, if successfully completed, should lead to a reduction in monthly lease payments of around 30% compared with year end 2019. In addition, the Company renegotiated the contract with its IT service provider and was able to reduce fixed costs by around 37% compared with the end of the financial year 2019. Last but not least, initial calculations show improvements in manufacturing costs of up to 10 % for selected fast-moving products.
 

Securing financing and thus aap's continued existence has top priority for the Management Board. In this connection, aap's core shareholders already granted first shareholder loans of EUR 0.4 million in April. In addition, aap announced a few days ago the issue of a convertible bond with a total volume of up to around EUR 2.6 million. The convertible bond can be subscribed to at an issue price of EUR 1.75 until August 26. In this way aap offers its shareholders the opportunity to participate in the financing measure at an attractive discount on the assumed future stock market price of around EUR 3.50 after the capital reduction resolved by the Annual General Meeting and to be entered in the commercial register in the next step. Individual shareholders have already committed themselves in advance to the subscription of convertible bonds with a volume of EUR 1.25 million, which corresponds to approx. 50% of the total transaction volume. In addition, aap has begun with the partial sale of excess capacities of its machinery that may lead to an inflow of liquid funds of up to EUR 0.3 million in the fourth quarter of 2020. In addition, the Management Board is currently working intensively on various other financing and cost-saving options. In particular, these include a committed interest-free loan from Investitionsbank Berlin (IBB) from the "Rescue Aid Corona Emergency Aid Package I" program, which is subject to certain challenging conditions, and far advanced negotiations on concluding a development and supply contract with a world-leading U.S. medical technology company, which is linked to the availability of sufficient financial resources at least for the duration of the development project. At the same time, the Management Board is currently in talks about possible corporate transactions (e.g. mergers, share or asset deals and carve-outs).
 


Outlook

Based on the business development in the first half of the year, the Management Board now expects sales for the full year 2020 to be in the upper half of the guidance of EUR 8 million to EUR 10 million. Mainly due to the extensive one-time expenses, the Management Board expects EBITDA to be at the lower end of the guidance of EUR -6.7 million to EUR -5.5 million. However, it should be noted that the forecast data on hand are characterised by a high degree of uncertainty. At this point in time, it is very difficult to assess the further course of the worldwide COVID-19 pandemic. For example, in the second half of 2020 there could be a second wave, feared by some virologists and experts, which in the worst case could lead to a renewed lockdown with corresponding negative consequences for the economy.
 

Last but not least, the Management Board aims to reorganise aap also on a structural level and to align it on the three pillars of its innovative platform technologies in future. The three technologies LOQTEQ(R), antibacterial silver coating and resorbable magnesium implants shall be transferred to separate subsidiaries and managed independently under the aap holding company umbrella. This makes it possible to manage the individual technologies more flexibly and in a more targeted manner and to implement the aimed co-financing for the silver coating and magnesium implant technologies.



[1] Relating to sales revenues, changes in inventories of finished and unfinished products and cost of materials / purchased services.
[2] Excluding restructuring expenses.
[3] Excluding restructuring and refinancing costs as well as one-time expenses in connection with the revision of the QM system.
[4] The disclosure of the other sales revenues still reported in the previous year no longer applies and are now allocated to the individual regions.
[5] In the previous year, sales to Puerto Rico were reported as part of North America (distributors); from Q3/2019 as part of RoW (= Rest of World).


----------------------------------------------------------------
aap
Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.


For inquiries please contact:

aap Implantate AG; Fabian Franke; Manager Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49/30/750 19 - 134; Fax: +49/30/750 19 - 290; f.franke@aap.de
 


14.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Unternehmen im Fokus

Wasserstoff-Rendite mit HPS

Spätestens mit Veröffentlichung der nationalen Wasserstoffstrategie rücken sämtliche „Wasserstoff-Unternehmen“ verstärkt in den Fokus der Investoren.
Das in Berlin ansässige Unternehmen HPS Home Power Solutions setzt Wasserstoff als saisonales Speichermedium für das autarke und vollständig CO2-freie Energieversorgungssystem picea® in Ein- bis Zweifamilienhäusern ein.
Dieses weltweit erste Solar-Wasserstoffkraftwerk für zuhause erlaubt mit einer Solaranlage eine dezentrale vollständige Stromversorgung über das gesamte Jahr und unterstützt dabei sogar zusätzlich die Wärmeversorgung im Haus.
Zur Finanzierung des laufenden Markteintritts und des weiteren Wachstums begibt HPS ein Nachrangdarlehen von bis zu 4 Mio. € über die Plattform GLS Crowd und verzinst das eingeworbene Kapital ab einem Einsatz von 250 € mit 7 % über eine Laufzeit von 5 Jahren. Die Zeichnungsfrist beginnt am 03.11.2020 um 10:30 Uhr.

Hinweis gemäß § 12 Abs. 2 Vermögensanlagengesetz: Der Erwerb dieser Vermögensanlage ist mit erheblichen Risiken verbunden und kann zum vollständigen Verlust des eingesetzten Vermögens führen.

Event im Fokus

14.-15.10.2020 Fachkonferenzen Finanzdienstleistungen und Technologie

11.-12.11.2020 Fachkonferenzen Software/IT und Branchenmix

Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen könnten die Fachkonferenzen im Herbst/Winter ggf. auch virtuell stattfinden.

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

News im Fokus

Linde Signs Second Long-Term Agreement to Supply Samsung in Pyeongtaek, South Korea

28. Oktober 2020, 12:00

Aktueller Webcast

HelloFresh SE

Q3 2020 Results Webcast

03. November 2020

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

28. Oktober 2020